Northwest Biotherapeutics, Inc.
NWBO
$0.23
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.94% | -5.63% | -101.92% | 17.63% | -23.68% |
| Total Depreciation and Amortization | 0.19% | -1.39% | 19.00% | 6.75% | 22.57% |
| Total Amortization of Deferred Charges | 6.92% | -42.01% | 134.43% | -24.52% | -32.18% |
| Total Other Non-Cash Items | 1,752.98% | 75.49% | 267.31% | -24.01% | -130.88% |
| Change in Net Operating Assets | 484.75% | 94.57% | 141.60% | 2,616.43% | -32.71% |
| Cash from Operations | 58.71% | 24.09% | -19.01% | 40.85% | -40.59% |
| Capital Expenditure | 41.65% | 61.09% | 81.34% | 59.73% | 58.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 41.65% | 61.09% | 81.34% | 59.73% | 58.29% |
| Total Debt Issued | -46.93% | 1.41% | 15.53% | -58.31% | 770.32% |
| Total Debt Repaid | 26.10% | -- | -118.29% | -40,000.00% | -132.71% |
| Issuance of Common Stock | 138.06% | 292.07% | 3,449.58% | 22,212.50% | 133.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -94.81% | 81.78% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -150.89% | -50.00% | -100.00% |
| Cash from Financing | -27.37% | -2.91% | 10.59% | -32.14% | 98.40% |
| Foreign Exchange rate Adjustments | -22,952.94% | -277.41% | 451.78% | -265.42% | 97.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 281.39% | 71.59% | 80.76% | -98.76% | 108.45% |